Browning Catherine E, Dixon Julie E, Malone Janine C, Callen Jeffrey P
Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S135-8. doi: 10.1016/j.jaad.2004.12.041.
Sweet's syndrome is a neutrophilic dermatosis characterized by tender, erythematous, pseudovesicular plaques that can be associated with hematologic malignancy. We report a patient with recalcitrant Sweet's syndrome that preceded the development of myelodysplastic syndrome by 30 months. The delay between the onset of Sweet's syndrome and the subsequent diagnosis of myelodysplasia highlights the need for thorough and repeated evaluation for underlying malignancy in patients with such a course. Although corticosteroids are the initial treatment of choice, this patient's eruption was only partially responsive to high-dose prednisone and was refractory to metronidazole, dapsone, and methotrexate. Treatment with thalidomide resulted in complete resolution of the cutaneous lesions within one month of therapy.
斯威特综合征是一种嗜中性皮病，其特征为压痛性、红斑性、假水疱性斑块，可与血液系统恶性肿瘤相关。我们报告一名难治性斯威特综合征患者，该综合征在骨髓增生异常综合征发生前30个月出现。斯威特综合征发病与随后骨髓发育异常诊断之间的延迟突出表明，对于有此类病程的患者，需要对潜在恶性肿瘤进行全面且反复的评估。尽管皮质类固醇是初始治疗的首选，但该患者的皮疹仅对高剂量泼尼松部分有反应，对甲硝唑、氨苯砜和甲氨蝶呤均无效。沙利度胺治疗使皮肤病变在治疗后1个月内完全消退。
